Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMPH NASDAQ:HROW NASDAQ:INBX NASDAQ:VERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$30.62+1.2%$24.60$20.39▼$53.96$1.42B0.76638,844 shs290,925 shsHROWHarrow$39.00+0.0%$34.67$20.85▼$59.23$1.44B0.41671,756 shs348,754 shsINBXInhibrx Biosciences$28.20+1.1%$21.50$10.81▼$28.29$408.48M0.24106,458 shs77,071 shsVERAVera Therapeutics$21.64-2.9%$22.19$18.53▼$51.61$1.38B1.171.74 million shs2.12 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals0.00%+0.39%+46.16%+18.32%-36.94%HROWHarrow0.00%-0.31%+22.80%+38.10%-1.40%INBXInhibrx Biosciences0.00%+12.80%+28.65%+107.96%+102.01%VERAVera Therapeutics0.00%-4.12%+4.09%+13.77%-41.04%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMPHAmphastar Pharmaceuticals3.298 of 5 stars1.21.00.03.73.64.21.3HROWHarrow3.3808 of 5 stars4.61.00.00.03.22.50.6INBXInhibrx Biosciences1.5989 of 5 stars0.03.00.04.62.22.50.0VERAVera Therapeutics3.7684 of 5 stars4.53.00.00.02.94.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPHAmphastar Pharmaceuticals 2.40Hold$31.603.20% UpsideHROWHarrow 3.13Buy$64.6765.81% UpsideINBXInhibrx Biosciences 2.00HoldN/AN/AVERAVera Therapeutics 2.90Moderate Buy$63.00191.13% UpsideCurrent Analyst Ratings BreakdownLatest INBX, HROW, VERA, and AMPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/26/2025AMPHAmphastar PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$28.00 ➝ $32.008/22/2025INBXInhibrx BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform8/14/2025HROWHarrowZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/14/2025HROWHarrowBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$62.00 ➝ $63.008/13/2025HROWHarrowHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$60.00 ➝ $64.008/12/2025AMPHAmphastar PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$36.008/8/2025AMPHAmphastar PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$30.00 ➝ $25.008/7/2025VERAVera TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$56.00 ➝ $53.008/4/2025VERAVera TherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Peer Perform7/11/2025HROWHarrowCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$76.006/12/2025HROWHarrowBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$62.00(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPHAmphastar Pharmaceuticals$722.68M1.97$5.00 per share6.12$16.29 per share1.88HROWHarrow$199.61M7.23$0.14 per share285.21$1.33 per share29.32INBXInhibrx Biosciences$200K2,041.68$117.50 per share0.24$4.73 per share5.96VERAVera TherapeuticsN/AN/AN/AN/A$7.34 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPHAmphastar Pharmaceuticals$159.52M$2.6711.479.31N/A18.64%20.76%9.68%11/5/2025 (Estimated)HROWHarrow-$17.48M-$0.25N/A97.50N/A-4.49%-2.18%-0.35%11/12/2025 (Estimated)INBXInhibrx Biosciences$1.69B-$10.58N/AN/AN/AN/A-137.83%-76.31%11/13/2025 (Estimated)VERAVera Therapeutics-$152.15M-$3.58N/AN/AN/AN/A-46.70%-39.46%11/6/2025 (Estimated)Latest INBX, HROW, VERA, and AMPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025INBXInhibrx Biosciences-$2.92-$1.85+$1.07-$1.85N/A$1.30 million8/11/2025Q2 2025HROWHarrow$0.01$0.24+$0.23$0.13$64.23 million$63.74 million8/5/2025Q2 2025VERAVera Therapeutics-$0.82-$1.20-$0.38-$1.20N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/AINBXInhibrx BiosciencesN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPHAmphastar Pharmaceuticals0.803.292.21HROWHarrow0.780.620.58INBXInhibrx Biosciences1.454.984.98VERAVera Therapeutics0.1617.0317.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPHAmphastar Pharmaceuticals65.09%HROWHarrow72.76%INBXInhibrx Biosciences82.46%VERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipAMPHAmphastar Pharmaceuticals27.50%HROWHarrow15.16%INBXInhibrx Biosciences17.09%VERAVera Therapeutics16.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPHAmphastar Pharmaceuticals2,02846.50 million33.71 millionOptionableHROWHarrow18037.00 million31.39 millionOptionableINBXInhibrx Biosciences16614.48 million12.01 millionOptionableVERAVera Therapeutics4063.82 million53.42 millionOptionableINBX, HROW, VERA, and AMPH HeadlinesRecent News About These CompaniesTri Locum Partners LP Invests $3.61 Million in Vera Therapeutics, Inc. $VERAAugust 30 at 8:04 AM | marketbeat.comNuveen LLC Acquires New Position in Vera Therapeutics, Inc. $VERAAugust 30 at 3:31 AM | marketbeat.comWalleye Capital LLC Acquires New Stake in Vera Therapeutics, Inc. $VERAAugust 29 at 5:20 AM | marketbeat.comAmerican Century Companies Inc. Sells 51,490 Shares of Vera Therapeutics, Inc. $VERAAugust 29 at 3:46 AM | marketbeat.comVera Therapeutics, Inc. $VERA Shares Bought by Price T Rowe Associates Inc. MDAugust 28 at 5:06 AM | marketbeat.comEvercore ISI Sticks to Their Buy Rating for Vera Therapeutics (VERA)August 27, 2025 | theglobeandmail.comVera Therapeutics to Participate at Upcoming Investor ConferencesAugust 26, 2025 | globenewswire.comVera Therapeutics, Inc. $VERA Shares Bought by T. Rowe Price Investment Management Inc.August 26, 2025 | marketbeat.comRussell Investments Group Ltd. Purchases 127,646 Shares of Vera Therapeutics, Inc. $VERAAugust 26, 2025 | marketbeat.comRusfertide Earns Breakthrough Therapy Designation in Polycythemia VeraAugust 26, 2025 | curetoday.comCVanguard Group Inc. Cuts Stock Position in Vera Therapeutics, Inc. $VERAAugust 26, 2025 | marketbeat.comVera Therapeutics: Institutional Confidence Meets Analytical SkepticismAugust 25, 2025 | aktiencheck.deAVera Therapeutics, Inc. $VERA Stake Boosted by Algert Global LLCAugust 24, 2025 | marketbeat.com19,597 Shares in Vera Therapeutics, Inc. $VERA Acquired by Fox Run Management L.L.C.August 21, 2025 | marketbeat.comLord Abbett & CO. LLC Has $3.57 Million Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)August 19, 2025 | marketbeat.comCan Vera Therapeutics’ (VERA) Widening Losses Challenge Its Path to Sustainable Growth?August 19, 2025 | finance.yahoo.comDeutsche Bank AG Purchases 82,483 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)August 15, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of "Moderate Buy" by AnalystsAugust 10, 2025 | marketbeat.comFY2025 EPS Estimates for VERA Cut by Cantor FitzgeraldAugust 9, 2025 | marketbeat.comHC Wainwright Has Negative Estimate for VERA Q3 EarningsAugust 9, 2025 | marketbeat.comWhat is Lifesci Capital's Forecast for VERA Q3 Earnings?August 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesNFL and WWE Land on ESPN—The Impact on Disney and TKO StocksBy Dan Schmidt | August 12, 2025Should You Join Buffett and Invest in Constellation Brands?By Jordan Chussler | August 22, 20254 Semiconductor Stocks Earning Fresh Wall Street UpgradesBy Leo Miller | August 7, 2025BJ’s Wholesale Club Pulls Back to Trend: It’s Time for an EntryBy Thomas Hughes | August 25, 2025Monster Is Re-Energized: Can the Stock's Rally Continue?By Leo Miller | August 20, 2025INBX, HROW, VERA, and AMPH Company DescriptionsAmphastar Pharmaceuticals NASDAQ:AMPH$30.62 +0.36 (+1.19%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$30.64 +0.02 (+0.08%) As of 08/29/2025 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Harrow NASDAQ:HROW$39.00 +0.01 (+0.03%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$39.05 +0.05 (+0.13%) As of 08/29/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Inhibrx Biosciences NASDAQ:INBX$28.20 +0.32 (+1.15%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$28.19 -0.01 (-0.04%) As of 08/29/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.Vera Therapeutics NASDAQ:VERA$21.64 -0.65 (-2.92%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$22.06 +0.42 (+1.94%) As of 08/29/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
